Galderma Group 

€31.8
10
-€0.4-1.24% Thursday 07:55

Statistics

Day High
31.8
Day Low
31.8
52W High
37
52W Low
14.8
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
0.04%
Dividend
0.01

Upcoming

Dividends

0.04%Dividend Yield
May 25
€0.01
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

5MarExpected
Q2 2024
Q4 2024
Q2 2025
Q4 2025
0.81
1.12
1.43
1.74
Expected EPS
1.35439425
Actual EPS
1.7441324999999999

Financials

11.78%Profit Margin
Profitable
2023
2024
2025
8.87BRevenue
1.04BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PY30.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson offers a wide range of skincare products through its consumer health division, directly competing with Galderma's offerings in the dermatological care market.
Novartis
NVS
Mkt Cap237.61B
Novartis, former parent company of Galderma, has a strong presence in the healthcare sector, including dermatology, competing in therapeutic areas similar to Galderma.
Pfizer
PFE
Mkt Cap140.15B
Pfizer competes in the pharmaceuticals sector including dermatology, offering products that overlap with Galderma’s therapeutic solutions.
Merck
MRK
Mkt Cap214.76B
Merck operates in the healthcare and pharmaceutical sectors with products that compete in dermatological conditions, a key area for Galderma.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb competes in various therapeutic areas including those that overlap with Galderma’s dermatology-focused portfolio.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly competes in the pharmaceutical field with a focus on medical dermatology, offering treatments that can compete with Galderma’s products.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a diversified healthcare portfolio that includes skin health products, competing with Galderma in the dermatology market.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates broadly in the pharmaceutical sector, including areas that compete with Galderma’s dermatological treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals focuses on innovative treatments, including for skin diseases, which puts it in competition with Galderma’s dermatology products.

About

Show more...
CEO
ISIN
US36321W1053
WKN
000A40C38

Listings

0 Comments

Share your thoughts

FAQ

What is Galderma Group stock price today?
The current price of PY30.F is €31.8 EUR — it has decreased by -1.24% in the past 24 hours. Watch Galderma Group stock price performance more closely on the chart.
What is Galderma Group stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Galderma Group stocks are traded under the ticker PY30.F.
Is Galderma Group stock price growing?
PY30.F stock has risen by +2.58% compared to the previous week, the month change is a +4.61% rise, over the last year Galderma Group has showed a +79.66% increase.
When is the next Galderma Group earnings date?
Galderma Group is going to release the next earnings report on July 23, 2026.
What were Galderma Group earnings last quarter?
PY30.F earnings for the last quarter are 1.74 EUR per share, whereas the estimation was 1.35 EUR resulting in a +28.78% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Galderma Group revenue for the last year?
Galderma Group revenue for the last year amounts to 8.87B EUR.
What is Galderma Group net income for the last year?
PY30.F net income for the last year is 1.04B EUR.
Does Galderma Group pay dividends?
Yes, PY30.F dividends are paid annual. The last dividend per share was 0.01 EUR. As of today, Dividend Yield (FWD)% is 0.04%.
When did Galderma Group complete a stock split?
Galderma Group has not had any recent stock splits.